242 related articles for article (PubMed ID: 16461300)
1. Increased platelet and leukocyte activation as contributing mechanisms for thrombosis in essential thrombocythemia and correlation with the JAK2 mutational status.
Arellano-Rodrigo E; Alvarez-Larrán A; Reverter JC; Villamor N; Colomer D; Cervantes F
Haematologica; 2006 Feb; 91(2):169-75. PubMed ID: 16461300
[TBL] [Abstract][Full Text] [Related]
2. Increased platelet, leukocyte, and coagulation activation in primary myelofibrosis.
Alvarez-Larrán A; Arellano-Rodrigo E; Reverter JC; Domingo A; Villamor N; Colomer D; Cervantes F
Ann Hematol; 2008 Apr; 87(4):269-76. PubMed ID: 17899078
[TBL] [Abstract][Full Text] [Related]
3. Platelet turnover, coagulation factors, and soluble markers of platelet and endothelial activation in essential thrombocythemia: relationship with thrombosis occurrence and JAK2 V617F allele burden.
Arellano-Rodrigo E; Alvarez-Larrán A; Reverter JC; Colomer D; Villamor N; Bellosillo B; Cervantes F
Am J Hematol; 2009 Feb; 84(2):102-8. PubMed ID: 19105233
[TBL] [Abstract][Full Text] [Related]
4. The role of JAK2 V617F mutation, spontaneous erythropoiesis and megakaryocytopoiesis, hypersensitive platelets, activated leukocytes, and endothelial cells in the etiology of thrombotic manifestations in polycythemia vera and essential thrombocythemia.
Bellucci S; Michiels JJ
Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):381-98. PubMed ID: 16810614
[TBL] [Abstract][Full Text] [Related]
5. Automated assessment of the neutrophil and platelet activation status in patients with essential thrombocythemia.
Arellano-Rodrigo E; Alvarez-Larrán A; Reverter JC; Villamor N; Jou JM; Cervantes F
Platelets; 2012; 23(5):336-43. PubMed ID: 22059534
[TBL] [Abstract][Full Text] [Related]
6. The influence of low-dose aspirin and hydroxyurea on platelet-leukocyte interactions in patients with essential thrombocythemia.
Treliński J; Tybura M; Smolewski P; Robak T; Chojnowski K
Blood Coagul Fibrinolysis; 2009 Dec; 20(8):646-51. PubMed ID: 19741509
[TBL] [Abstract][Full Text] [Related]
7. Increased risk of recurrent thrombosis in patients with essential thrombocythemia carrying the homozygous JAK2 V617F mutation.
De Stefano V; Za T; Rossi E; Vannucchi AM; Ruggeri M; Elli E; Micò C; Tieghi A; Cacciola RR; Santoro C; Vianelli N; Guglielmelli P; Pieri L; Scognamiglio F; Cacciola E; Rodeghiero F; Pogliani EM; Finazzi G; Gugliotta L; Leone G; Barbui T;
Ann Hematol; 2010 Feb; 89(2):141-6. PubMed ID: 19582452
[TBL] [Abstract][Full Text] [Related]
8. JAK2 mutation in essential thrombocythaemia: clinical associations and long-term prognostic relevance.
Wolanskyj AP; Lasho TL; Schwager SM; McClure RF; Wadleigh M; Lee SJ; Gilliland DG; Tefferi A
Br J Haematol; 2005 Oct; 131(2):208-13. PubMed ID: 16197451
[TBL] [Abstract][Full Text] [Related]
9. JAK2-V617F mutation analysis of granulocytes and platelets from patients with chronic myeloproliferative disorders: advantage of studying platelets.
Toyama K; Karasawa M; Yamane A; Irisawa H; Yokohama A; Saitoh T; Handa H; Matsushima T; Sawamura M; Miyawaki S; Murakami H; Nojima Y; Tsukamoto N
Br J Haematol; 2007 Oct; 139(1):64-9. PubMed ID: 17854308
[TBL] [Abstract][Full Text] [Related]
10. JAK2V617F mutation in platelets from essential thrombocythemia patients: correlation with clinical features and analysis of STAT5 phosphorylation status.
Heller PG; Lev PR; Salim JP; Kornblihtt LI; Goette NP; Chazarreta CD; Glembotsky AC; Vassallu PS; Marta RF; Molinas FC
Eur J Haematol; 2006 Sep; 77(3):210-6. PubMed ID: 16923108
[TBL] [Abstract][Full Text] [Related]
11. Clinical and laboratory features, pathobiology of platelet-mediated thrombosis and bleeding complications, and the molecular etiology of essential thrombocythemia and polycythemia vera: therapeutic implications.
Michiels JJ; Berneman Z; Van Bockstaele D; van der Planken M; De Raeve H; Schroyens W
Semin Thromb Hemost; 2006 Apr; 32(3):174-207. PubMed ID: 16673274
[TBL] [Abstract][Full Text] [Related]
12. High prevalence of arterial thrombosis in JAK2 mutated essential thrombocythaemia: independence of the V617F allele burden.
Larsen TS; Pallisgaard N; Møller MB; Hasselbalch HC
Hematology; 2008 Apr; 13(2):71-6. PubMed ID: 18616871
[TBL] [Abstract][Full Text] [Related]
13. JAK2V617F allele burden is associated with thrombotic mechanisms activation in polycythemia vera and essential thrombocythemia patients.
Coucelo M; Caetano G; Sevivas T; Almeida Santos S; Fidalgo T; Bento C; Fortuna M; Duarte M; Menezes C; Ribeiro ML
Int J Hematol; 2014 Jan; 99(1):32-40. PubMed ID: 24277659
[TBL] [Abstract][Full Text] [Related]
14. Determinants of platelet conjugate formation with polymorphonuclear leukocytes or monocytes in whole blood.
Izzi B; Pampuch A; Costanzo S; Vohnout B; Iacoviello L; Cerletti C; de Gaetano G
Thromb Haemost; 2007 Dec; 98(6):1276-84. PubMed ID: 18064325
[TBL] [Abstract][Full Text] [Related]
15. Prognostic utility of spontaneous erythroid colony formation and JAK2 mutational analysis for thrombotic events in essential thrombocythaemia.
Weston H; Cowell V; Grimmett K; Saal R; Jones M; Mills T; Gill D; Marlton P; Bird R; Mollee P
Intern Med J; 2011 May; 41(5):408-15. PubMed ID: 20681956
[TBL] [Abstract][Full Text] [Related]
16. Is the absence of JAK2 mutation a risk factor for bleeding in essential thrombocythemia? An analysis of 106 patients.
Patriarca A; Pompetti F; Malizia R; Iuliani O; Di Marzio I; Spadano A; Dragani A
Blood Transfus; 2010 Jan; 8(1):21-7. PubMed ID: 20104275
[TBL] [Abstract][Full Text] [Related]
17. The presence of the JAK2 V617F mutation is associated with a higher haemoglobin and increased risk of thrombosis in essential thrombocythaemia.
Cheung B; Radia D; Pantelidis P; Yadegarfar G; Harrison C
Br J Haematol; 2006 Jan; 132(2):244-5. PubMed ID: 16398659
[No Abstract] [Full Text] [Related]
18. Elevation of endothelial microparticles, platelets, and leukocyte activation in patients with venous thromboembolism.
Chirinos JA; Heresi GA; Velasquez H; Jy W; Jimenez JJ; Ahn E; Horstman LL; Soriano AO; Zambrano JP; Ahn YS
J Am Coll Cardiol; 2005 May; 45(9):1467-71. PubMed ID: 15862420
[TBL] [Abstract][Full Text] [Related]
19. Comparison of coated-platelet levels in patients with essential thrombocythemia with and without hydroxyurea treatment.
Reményi G; Szász R; Debreceni IB; Szarvas M; Batár P; Nagy B; Kappelmayer J; Udvardy M
Platelets; 2013; 24(6):486-92. PubMed ID: 23216455
[TBL] [Abstract][Full Text] [Related]
20. Concomitant neutrophil JAK2 mutation screening and PRV-1 expression analysis in myeloproliferative disorders and secondary polycythaemia.
Tefferi A; Sirhan S; Lasho TL; Schwager SM; Li CY; Dingli D; Wolanskyj AP; Steensma DP; Mesa R; Gilliland DG
Br J Haematol; 2005 Oct; 131(2):166-71. PubMed ID: 16197445
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
